| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Ramaswamy Vivek | 10%+ Owner | C/O STEVE ROBERTS, 700 PENNSYLVANIA AVE., SE STE. 440, WASHINGTON | /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy | 15 Dec 2025 | 0001635075 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ROIV | Common Shares | Options Exercise | $23,707,682 | +1,869,691 | +5.6% | $12.68 | 35,523,447 | 11 Dec 2025 | Direct | |
| transaction | ROIV | Common Shares | Sale | $16,752,433 | -774,142 | -2.2% | $21.64 | 34,749,305 | 11 Dec 2025 | Direct | F1 |
| transaction | ROIV | Common Shares | Other | $23,707,702 | -1,095,550 | -3.2% | $21.64 | 33,653,755 | 11 Dec 2025 | Direct | F1, F2 |
| transaction | ROIV | Common Shares | Options Exercise | $59,250,140 | +4,672,724 | +14% | $12.68 | 38,326,479 | 12 Dec 2025 | Direct | |
| transaction | ROIV | Common Shares | Sale | $43,389,842 | -1,975,858 | -5.2% | $21.96 | 36,350,621 | 12 Dec 2025 | Direct | F3 |
| transaction | ROIV | Common Shares | Other | $59,223,177 | -2,696,866 | -7.4% | $21.96 | 33,653,755 | 12 Dec 2025 | Direct | F2, F3 |
| transaction | ROIV | Common Shares | Options Exercise | $10,555,504 | +832,453 | +2.5% | $12.68 | 34,486,208 | 15 Dec 2025 | Direct | |
| transaction | ROIV | Common Shares | Sale | $7,800,077 | -353,745 | -1% | $22.05 | 34,132,463 | 15 Dec 2025 | Direct | F4 |
| transaction | ROIV | Common Shares | Other | $10,555,511 | -478,708 | -1.4% | $22.05 | 33,653,755 | 15 Dec 2025 | Direct | F2, F4 |
| holding | ROIV | Common Shares | 13,357,857 | 11 Dec 2025 | Spousal | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ROIV | Stock Option (Right to Buy) | Options Exercise | $0 | -1,869,691 | -6.3% | $0.000000 | 27,655,404 | 11 Dec 2025 | Common Stock | 1,869,691 | $12.68 | Direct | F6, F7 |
| transaction | ROIV | Stock Option (Right to Buy) | Options Exercise | $0 | -4,672,724 | -17% | $0.000000 | 22,982,680 | 12 Dec 2025 | Common Stock | 4,672,724 | $12.68 | Direct | F6, F7 |
| transaction | ROIV | Stock Option (Right to Buy) | Options Exercise | $0 | -832,453 | -3.6% | $0.000000 | 22,150,227 | 15 Dec 2025 | Common Stock | 832,453 | $12.68 | Direct | F6, F7 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. |
| F2 | Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive. |
| F5 | Represents the quantity of shares held indirectly only. |
| F6 | Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |
| F7 | All options exercised by the reporting person would have expired in March 2026 if not exercised. |